MorphoSys to Present at Three Investor Conferences in June

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that its management will give company presentations at three upcoming investor conferences in June 2009. Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG, will present at BioEquity Europe 2009, being held June 9-10 in Munich, Germany, and at the Jefferies 3rd Annual Healthcare Conference, being held June 17-18 in New York, USA. Dave Lemus, Chief Financial Officer of MorphoSys AG, will present at the Deutsche Bank German & Austrian Corporate Conference, being held June 23 in Frankfurt, Germany. BioEquity Europe 2009 Date: Tuesday, June 9, 2009 Time: 02:30pm BST (09:30am EDT; 03:30pm CET) Venue: Hilton Munich Park Hotel, Munich, Germany Jefferies 3rd Annual Healthcare Conference Date: Thursday, June 18, 2009 Time: 08:15 pm BST (03:15 pm EDT; 09:15 pm CET) Venue: Mandarin Oriental Hotel, New York, USA Deutsche Bank German & Austrian Corporate Conference Date: Tuesday, June 23, 2009 Time: 11:30am BST (06:30am EDT; 12:30pm CET) Venue: Hilton Hotel, Frankfurt, Germany Presentations as well as live and archived webcasts of the presentations will be provided at For further information please contact: Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & Investor Relations, Tel: +49 (0) 89 / 899 27-122, or Mario Brkulj, Senior Manager Corporate Communications & Investor Relations, Tel: +49 (0) 89 / 899 27-454, About MorphoSys: MorphoSys is a publicly traded biotechnology company focused on the generation of fully human antibodies as a means to discover and develop innovative antibody-based drugs against life-threatening diseases. MorphoSys's goal is to establish HuCAL as the technology of choice for antibody generation in research, diagnostics and therapeutic applications. The Company currently has therapeutic and research alliances with the majority of the world's largest pharmaceutical companies including Boehringer Ingelheim, Centocor/Johnson & Johnson, Novartis, Pfizer and Roche. Within these partnerships, more than 50 therapeutic antibody programs are ongoing in which MorphoSys participates through exclusive license and milestones payments as well as royalties on any end products. Additionally, MorphoSys is active in the antibody research market through its AbD Serotec business unit. The business unit has operations in Germany (Munich), the U.S. (Raleigh, NC) and U.K. (Oxford). For further information please visit HuCAL®, HuCAL GOLD®, HuCAL PLATINUM® and RapMAT® are registered trademarks of MorphoSys AG This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned. This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.